Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Alector, Inc.
  6. Summary
    ALEC   US0144421072

ALECTOR, INC.

(ALEC)
  Report
Real-time Estimate Cboe BZX  -  01:32 2022-08-09 pm EDT
12.61 USD   -3.93%
08/04ALECTOR : Q2 Earnings Snapshot
AQ
08/04ALECTOR : August 2022 Corporate Presentation
PU
08/04ALECTOR : Reports Second Quarter 2022 Financial Results and Provides Business Update - Form 8-K
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/03/2022 08/04/2022 08/05/2022 08/08/2022 08/09/2022 Date
11.23(c) 11.33(c) 13.06(c) 13.12(c) 12.64 Last
569 696 441 186 818 585 619 872 158 736 Volume
+6.95% +0.89% +15.27% +0.46% -3.66% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 165 M - -
Net income 2022 -98,5 M - -
Net cash position 2022 914 M - -
P/E ratio 2022 -10,5x
Yield 2022 -
Sales 2023 198 M - -
Net income 2023 -112 M - -
Net cash position 2023 922 M - -
P/E ratio 2023 -18,9x
Yield 2023 -
Capitalization 1 083 M 1 083 M -
EV / Sales 2022 1,03x
EV / Sales 2023 0,81x
Nbr of Employees 269
Free-Float 88,9%
More Financials
Company
Alector, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. The Company is engaged in developing therapies designed to counteract these pathologies by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and... 
Read more
More about the company
Ratings of Alector, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about ALECTOR, INC.
08/04ALECTOR : Q2 Earnings Snapshot
AQ
08/04ALECTOR : August 2022 Corporate Presentation
PU
08/04ALECTOR : Reports Second Quarter 2022 Financial Results and Provides Business Update - For..
PU
08/04ALECTOR, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
08/04Alector, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June..
CI
08/04Alector Reports Second Quarter 2022 Financial Results and Provides Business Update
GL
08/04Alector Reports Second Quarter 2022 Financial Results and Provides Business Update
AQ
07/11Citigroup Adjusts Alector's Price Target to $19 From $34, Reiterates Buy Rating
MT
07/08Alector Says Partner AbbVie Ends One of Two Programs in Alzheimer's Disease Collaborati..
MT
07/07ALECTOR : July 2022 Corporate Presentation
PU
07/07ALECTOR, INC. : Other Events (form 8-K)
AQ
07/07Alector, Inc Developing AL003 to Treat Patients with Alzheimer's Disease as One of Two ..
CI
07/07Mizuho Securities Initiates Alector at Buy with $15 Price Target
MT
07/06Mizuho Initiates Alector with Buy Rating, $15 Price Target, Represents 'Classic' Risk/R..
MT
06/24ALECTOR, INC.(NASDAQGS : ALEC) added to Russell Microcap Growth Index
CI
More news
News in other languages on ALECTOR, INC.
08/04Alector, Inc. annonce ses résultats pour le deuxième trimestre et les six mois terminés..
07/07Alector, Inc développe AL003 pour traiter les patients atteints de la maladie d'Alzheim..
05/05Alector, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
04/13Les actions d'Alector chutent après que Goldman Sachs ait commencé à les couvrir à vend..
03/29Alector nomme un médecin-chef
More news
Analyst Recommendations on ALECTOR, INC.
More recommendations
Chart ALECTOR, INC.
Duration : Period :
Alector, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALECTOR, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 13,12 $
Average target price 24,96 $
Spread / Average Target 90,2%
EPS Revisions
Managers and Directors
Arnon Rosenthal Chief Executive Officer & Director
Saraswati Kenkare-Mitra President, Head-Research & Development
Marc Edward Grasso Chief Financial, Accounting & Business Officer
Tillman U. Gerngross Chairman
Charles Wolfus VP-Technology & Digital Health
Sector and Competitors
1st jan.Capi. (M$)
ALECTOR, INC.-36.46%1 083
GILEAD SCIENCES, INC.-15.87%77 266
VERTEX PHARMACEUTICALS31.16%75 386
REGENERON PHARMACEUTICALS, INC.-2.84%67 420
BIONTECH SE-28.97%41 143
WUXI APPTEC CO., LTD.-20.64%40 375